NeuroKaire To Showcase Breakthrough Blood Test That Ends the Antidepressant Guessing Game at HLTH 2026 Conference

NeuroKaire is presenting its BrightKaire blood test at the HLTH 2026 conference, which uses AI and patient-derived neurons to predict antidepressant effectiveness. The technology aims to eliminate the trial-and-error process currently used to prescribe mental health medications.
Why it matters
Precision medicine in psychiatry could significantly improve patient outcomes and reduce the economic burden of ineffective mental health treatments.
Company leverages patient-derived neurons and AI to support antidepressant choice
KEARNY, N.J. and TEL AVIV, Israel, Nov. 15, 2026 (GLOBE NEWSWIRE) -- NeuroKaire, turning a simple blood draw into a window on each patient’s brain, today announced its participation at the HLTH 2026 Conference taking place November 15-18, 2026 at the Venetian Expo in Las Vegas. Company leadership will meet with health system leaders, payers, investors and clinical innovators to demonstrate how its proprietary platform reads neuroplasticity in each patient’s own neurons to guide them to the right antidepressant.
For millions of patients with depression finding an effective medication involves an agonizing years-long cycle of trial and error. This delay in effective treatment causes worse clinical outcomes, elevates suicide risks, drives billions in avoidable healthcare utilization and increases workplace absenteeism.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in